Erythema Nodosum Leprosum
0
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Mission TherapeuticsUK - Cambridge
3 programsMethotrexateN/A1 trial
montelukast in treatment of ENL reactionN/A1 trial
CC-11050PHASE_21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Mission TherapeuticsCC-11050
Mission TherapeuticsMethotrexate
Mission Therapeuticsmontelukast in treatment of ENL reaction
Clinical Trials (3)
Total enrollment: 660 patients across 3 trials
CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum
Start: Jan 2018Est. completion: Dec 202450 patients
Phase 2Unknown
Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum
Start: Jan 2023Est. completion: Oct 2025550 patients
N/AActive Not Recruiting
Montelukast in ENL Reaction
Start: Dec 2006Est. completion: Jun 200960 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.